Table 5 Sensitivity analysis results: percentage difference between “New and generic drugs scenarios”, and the scenario that does not consider new and generic drugs
Scenario | 2015 | 2016 | 2017 | 2018 | 2019 | 5 Years mean difference |
|---|---|---|---|---|---|---|
Base case | −0.6 % | −2.1 % | −2.4 % | −6.1 % | −12.8 % | −4.8 % |
Increased costs | −0.5 % | −1.4 % | −1.3 % | −3.9 % | −8.4 % | −3.1 % |
Decreased costs | −0.7 % | −3.0 % | −3.6 % | −9.1 % | −19.0 % | −7.1 % |
Increased switch rates | −2.3 % | −3.9 % | −4.2 % | −7.7 % | −14.6 % | −6.6 % |
Decreased switch rates | 0.2 % | −0.7 % | −0.9 % | −4.0 % | −9.6 % | −3.0 % |
Increased costs and decreased switch rates | 0.2 % | −0.1 % | 0.0 % | −1.9 % | −5.5 % | −1.5 % |
Increased costs and switch rates | −2.1 % | −3.0 % | −3.0 % | −5.3 % | −9.7 % | −4.6 % |
Decreased costs and switch rates | 0.2 % | −1.2 % | −1.6 % | −6.2 % | −14.4 % | −4.7 % |
Decreased costs and increased switch rates | −2.9 % | −5.3 % | −5.9 % | −10.9 % | −20.7 % | −9.1 % |